Literature DB >> 1515989

Risk factors for failure of immediate breast reconstruction with prosthesis after total mastectomy for breast cancer.

L Barreau-Pouhaer1, M G Lê, M Rietjens, R Arriagada, G Contesso, R Martins, J Y Petit.   

Abstract

BACKGROUND: Immediate breast reconstruction (IBR) after mastectomy represents a clear improvement in the quality of life of patients with breast cancer, but prosthesis removal is relatively frequent. Therefore, it is important to identify risk factors related to this removal.
METHODS: A series of 142 patients treated with mastectomy and IBR at the Institut Gustave-Roussy between January 1976 and December 1988 were studied. Forty-seven had an in situ carcinoma, 93 an infiltrating carcinoma, and 2 a fibrosarcoma. IBR failures were defined as removal of the prosthesis, and early failures as removal during the first 7 weeks after IBR.
RESULTS: The early failure rate was significantly higher in patients with invasive carcinomas or fibrosarcomas than patients with in situ carcinomas (12% versus 0%, P = 0.04). The risk of late IBR failure was significantly higher in patients who had received postoperative radiation therapy than patients who did not (P = 0.0002). However, this increased risk applied only to women in whom the chest wall was exposed to radiation because of a high risk of recurrence.
CONCLUSION: It might be preferable to postpone breast reconstruction for patients with infiltrating breast carcinoma because early complications are not infrequent and could delay adjuvant chemotherapy. Late complications associated with chest wall irradiation could be avoided with the use of alternative techniques such as the transverse rectus abdominis myocutaneous (TRAM) flap procedure.

Entities:  

Mesh:

Year:  1992        PMID: 1515989     DOI: 10.1002/1097-0142(19920901)70:5<1145::aid-cncr2820700520>3.0.co;2-3

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  8 in total

1.  Update on breast reconstruction techniques and indications.

Authors:  Jean-Yves Petit; Mario Rietjens; Visnu Lohsiriwat; Piercarlo Rey; Cristina Garusi; Francesca De Lorenzi; Stefano Martella; Andrea Manconi; Benedetta Barbieri; Krishna B Clough
Journal:  World J Surg       Date:  2012-07       Impact factor: 3.352

Review 2.  New trends in breast cancer management: is the era of immediate breast reconstruction changing?

Authors:  Bohdan Pomahac; Abram Recht; James W May; Charles A Hergrueter; Sumner A Slavin
Journal:  Ann Surg       Date:  2006-08       Impact factor: 12.969

3.  Psychosocial sequelae of breast cancer and its treatment.

Authors:  A Moyer; P Salovey
Journal:  Ann Behav Med       Date:  1996-06

4.  Patient determinants as independent risk factors for postoperative complications of breast reconstruction.

Authors:  Andri Thorarinsson; Victoria Fröjd; Lars Kölby; Mattias Lidén; Anna Elander; Hans Mark
Journal:  Gland Surg       Date:  2017-08

5.  Immediate breast reconstruction by prosthesis: a safe technique for extensive intraductal and microinvasive carcinomas.

Authors:  K B Clough; D Bourgeois; M C Falcou; C Renolleau; J C Durand
Journal:  Ann Surg Oncol       Date:  1996-03       Impact factor: 5.344

Review 6.  A systematic review of complications of implant-based breast reconstruction with prereconstruction and postreconstruction radiotherapy.

Authors:  Adeyiza O Momoh; Raouf Ahmed; Brian P Kelley; Oluseyi Aliu; Kelley M Kidwell; Jeffrey H Kozlow; Kevin C Chung
Journal:  Ann Surg Oncol       Date:  2013-10-01       Impact factor: 5.344

7.  Survival benefit with radiation therapy in node-positive breast carcinoma patients.

Authors:  Mia Voordeckers; Vincent Vinh-Hung; Jan Lamote; Annette Bretz; Guy Storme
Journal:  Strahlenther Onkol       Date:  2009-10-06       Impact factor: 3.621

8.  Variation in physician-patient discussion of breast reconstruction.

Authors:  Judy Y Chen; Jennifer Malin; Patricia A Ganz; Clifford Ko; Diana Tisnado; May Lin Tao; Martha Timmer; John L Adams; Katherine L Kahn
Journal:  J Gen Intern Med       Date:  2008-11-21       Impact factor: 5.128

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.